Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo

BACKGROUND AND PURPOSE: Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy cyclophosphamide–doxorubicin–vincristine–prednisolone (CHOP) in the treatment of haematological tumours and is currently approved for the treatment of many haematolo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ackler, S, Mitten, MJ, Chen, J, Clarin, J, Foster, K, Jin, S, Phillips, DC, Schlessinger, S, Wang, B, Leverson, JD, Boghaert, ER
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2012
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575786/
https://ncbi.nlm.nih.gov/pubmed/22624727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.02048.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller